Aberrant promoter methylation of insulin‐like growth factor binding protein‐3 gene in human cancers
The DOI matches its Crossref record.
Abstract
Insulin‐like growth factor binding protein‐3 (IGFBP‐3) is postulated to be a mediator of growth suppression signals. Here, we examined the methylation status of IGFBP‐3 to correlate to clinicopathological factors in human cancers. The methylation status of IGFBP‐3 was determined by bisulfite DNA sequencing and was correlated with expression semi‐quantified by real‐time RT‐PCR to develop a methylation‐specific PCR (MSP) assay for IGFBP‐3. Using the MSP assay, we examined the methylation status of IGFBP‐3 in gastric cancer (GC), colorectal cancer (CRC), breast cancer (BC) and malignant mesothelioma (MM). IGFBP‐3 methylation was detected in 6 of 13 (46%) and 16 of 24 (67%) GC cell lines and tumors, respectively; 4 of 8 (50%) and 15 of 26 (58%) CRC cell lines and tumors, respectively; 3 of 11 (27%) and 7 of 39 (18%) BC cell lines and tumors, respectively and 1 of 5 (20%) and 18 of 56 (32%) MM cell lines and tumors, respectively. Interestingly, the methylation status of MM specimens from Japanese patients (75%, 12 out of 16 patients) was significantly higher than those from the USA (15%, 6 out of 40 patients) (p < 0.0001), suggesting the presence of ethnic differences in the IGFBP‐3 methylation status. We also found that IGFBP‐3 methylation was preferentially present in GCs arising in the lower‐third of the stomach (p = 0.079). In summary, our results showed that IGFBP‐3 methylation played an important role in the silencing of its expression, suggesting that IGFBP‐3 may act as a tumor suppressor gene in several human cancers examined. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Senescence-messaging secretome: SMS-ing cellular stress
Kuilman, T., & Peeper, D. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2560 · Cited by 909
Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human Disease
Jogie-Brahim, S., Feldman, D., & Oh, Y. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0028 · Cited by 323
Cortot, A. B., Repellin, C. E., Shimamura, T., Capelletti, M., Zejnullahu, K., Ercan, D., Christensen, J. G., Wong, K.-K., Gray, N. S., & Jänne, P. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2066 · Cited by 185
“IGFBP3 methylation studies Promoter methylation of IGFBP3 was evaluated using previously published methods and primers (27).”
Insulin Growth Factor Binding Protein 7 (IGFBP7)-Related Cancer and IGFBP3 and IGFBP7 Crosstalk
Jin, L., Shen, F., Weinfeld, M., & Sergi, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00727 · Cited by 123
IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways
Benatar, T., Yang, W., Amemiya, Y., Evdokimova, V., Kahn, H., Holloway, C., & Seth, A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1816-4 · Cited by 89
“The expression of both IGFBP3 and IGFBP7 is frequently decreased in tumors, often as a consequence of promoter methylation [56, 57].”
Background
Metadata
- Authors
- Tomii, K., Tsukuda, K., Toyooka, S., Dote, H., Hanafusa, T., Asano, H., Naitou, M., Doihara, H., Kisimoto, T., Katayama, H., Pass, H. I., Date, H., & Shimizu, N.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2006-11-09
- Volume
- 120
- Issue
- 3
- Pages
- 566-573
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1974631544
- Cited by
- 72
- References
- 0
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aberrant promoter methylation of insulin‐like growth factor binding protein‐3 gene in human cancers. https://app.cochat.ai/papers/10.1002/ijc.22341
- The paper
- Tomii, K., Tsukuda, K., Toyooka, S., Dote, H., Hanafusa, T., Asano, H., Naitou, M., Doihara, H., Kisimoto, T., Katayama, H., Pass, H. I., Date, H., & Shimizu, N. (2007). Aberrant promoter methylation of insulin‐like growth factor binding protein‐3 gene in human cancers. International Journal of Cancer. https://doi.org/10.1002/ijc.22341
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.